Category: 1 Minute-Read

Categories
1 Minute-Read

Corona Remedies lists at 38% premium on debut

Corona Remedies made a strong debut on Dalal Street on Monday, December 15, 2025, with shares opening at ₹1,470 on NSE and ₹1,452 on BSE, against the IPO price of ₹1,062, marking a 38% listing gain.

The ₹655-crore IPO, fully an offer-for-sale, was heavily oversubscribed, reflecting robust investor interest. Grey market data had also suggested strong demand ahead of listing.

The Gujarat-based pharma firm specializes in women’s healthcare and cardiometabolic medicines. Early trading showed sustained gains, indicating positive market sentiment for the stock.

Categories
1 Minute-Read

Nvidia may boost H200 chip output

Nvidia is considering increasing production of its H200 artificial intelligence chips amid strong demand from Chinese technology companies, including Alibaba and ByteDance, according to a media report.

Interest in the chips has picked up after the United States allowed their export to China under certain conditions and fees. The H200 chips are used for advanced AI computing and data centres.

However, Nvidia’s current output is limited as it focuses more on its next-generation chips. Any production increase would also depend on regulatory approvals and supply chain capacity, as Chinese firms look to secure more high-performance AI hardware.

Categories
1 Minute-Read

boAt financial gaps raise concerns before IPO

Auditors of consumer electronics brand boAt have highlighted differences between the company’s financial statements submitted to lenders and its internal records for 2023–2025.

The review also noted possible misuse of short-term funds for long-term purposes in subsidiaries and some unreported overseas transactions. boAt has begun addressing these issues by revising its filings and improving disclosures.

The findings come as the company prepares for a proposed IPO, planning to raise around ₹1,500 crore. While the discrepancies have drawn regulatory attention, boAt aims to resolve them before entering the market, ensuring investor confidence.

Categories
1 Minute-Read

Disney and OpenAI deal brings iconic characters to Sora

Disney and OpenAI have signed a major three-year agreement that will allow fans to create short AI-generated videos featuring more than 200 characters from Disney, Marvel, Pixar and Star Wars using OpenAI’s video model, Sora.

Disney will invest $1 billion in OpenAI and also use its technology to develop new products and improve Disney+ services. The partnership includes strict safeguards: no real actor voices or likenesses will be used.

Some user-created clips may be showcased on Disney+. The feature will launch in early 2026, marking one of the biggest collaborations between Hollywood and generative AI.

Categories
1 Minute-Read

IndiGo offers Rs 10,000 vouchers to passengers

IndiGo will issue Rs 10,000 travel vouchers to passengers severely affected by flight delays and cancellations between December 3 and 5.

The vouchers, valid for 12 months, can be used on any IndiGo flight. This offer is in addition to government-mandated compensation, which ranges from Rs 5,000 to Rs 10,000 for cancellations made less than 24 hours before departure.

Refunds for most cancelled flights have already been processed. IndiGo has gradually restored normal flight operations and said the vouchers are intended to rebuild trust and compensate customers impacted by the disruptions.

Categories
1 Minute-Read

IndiGo’s 10% cut barely trims flights

IndiGo’s planned 10% reduction in its winter schedule results in only a 2.35% drop in actual flights because the airline had not been using its full permitted capacity.

The DGCA had allowed IndiGo around 2,145 daily departures, but it consistently operated below 2,000 flights per day over the past year.

This means the mandated cut brings daily flights down only slightly, to about 1,931. Analysts estimate a revenue impact of ₹1,200–1,400 crore, or roughly 1.3–1.7% of annual earnings.

Overall, the headline cut appears steep, but its operational impact around IndiGo is limited.

Categories
1 Minute-Read

Aequs shares listed at 13% premium on day 1

Aequs’ shares debuted on the stock market on Dec 10 at ₹396, marking a 13% premium over its IPO price of ₹350.

Despite this positive listing, the stock fell short of grey market expectations, which had predicted a higher premium. The company’s IPO had garnered strong investor interest, being subscribed multiple times.

Aequs, an aerospace and engineering services firm, aims to leverage this listing to strengthen its market presence and fund expansion plans, including scaling operations and exploring new business opportunities.Analysts noted that while the listing was encouraging, it highlighted a gap between market anticipation and actual investor response.

Categories
1 Minute-Read

ICICI Prudential AMC IPO opens December 12

India’s largest asset management company, ICICI Prudential AMC, is launching its IPO on December 12, 2025, with anchor bidding on December 11.

The ₹10,602.65 crore offer is fully structured as an offer-for-sale, with Prudential Corporation Holdings offloading up to 4.9 crore shares. The price band is set at ₹2,061–₹2,165 per share, with retail investors allowed a minimum investment of ₹12,990 (6 shares per lot).

Allotment is expected by December 17, and listing on BSE and NSE is tentatively scheduled for December 19. The IPO’s GMP is reported at ₹119 over the issue price.

Categories
1 Minute-Read

Corona Remedies IPO

The Corona Remedies IPO, priced between ₹1,008–₹1,062 per share, saw robust demand, closing Day 3 with a 32× overall subscription.

The Non-Institutional Investor (NII) segment led the frenzy, oversubscribed 107×, while retail and qualified institutional buyers also showed strong interest.

Grey Market Premium (GMP) surged to around ₹30 per share, indicating high listing expectations. The IPO, valued at ₹655 crore through an offer-for-sale, reflects strong market confidence.

Investors are keenly watching the listing, but experts advise caution given the steep oversubscription and potential volatility post-listing.

Categories
1 Minute-Read

Neochem Bio shares spike 10% on market debut

Neochem Bio Solutions made a strong start on the stock market on Tuesday. Its shares opened at ₹108 each, marking a 10.2% premium over the IPO price of ₹98. The stock later rose to ₹111.20, giving early investors quick gains.

The company raised ₹44.97 crore through its IPO, issuing 45.88 lakh new shares. Funds from the IPO will be used for working capital, repaying borrowings, and general corporate purposes.

The IPO was highly subscribed, with overall demand 15.5 times the issue size. Qualified institutional buyers applied for 21.97 times, non-institutional investors for 21.15 times, and retail investors for 9.42 times of the shares offered.

Neochem Bio Solutions produces specialty performance chemicals for industries like textiles, home and personal care, water treatment, paints, construction, and more, with a portfolio of over 350 chemical formulations.